Lilly weight-loss pill orforglipron could get FDA approval in 2026, CEO Dave Ricks says

by
Eli Lilly & Co., the Fortune 500 pharma firm that manufactures weight-loss injection Zepbound (tirzepatide), has a comparable oral medication in the works that could be approved by the FDA as early as 2026, CEO Dave Ricks told Bloomberg TV on Jan. 13, 2025.

Eli Lilly & Co., the Fortune 500 pharma firm that manufactures weight-loss injection Zepbound (tirzepatide), has a comparable oral medication in the works that could be approved by the FDA as early as 2026, CEO Dave Ricks told Bloomberg TV on Jan. 13, 2025.

Gam1983/Getty Images

https://fortune.com/img-assets/wp-content/uploads/2025/01/GettyImages-861888786-e1737042101686.jpg?resize=1200,600

2025-01-22 01:05:00

Leave a Comment